/Edwards%20Lifesciences%20Corp%20logo%20on%20phone-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Edwards Lifesciences has notably outperformed the broader market over the past year, and analysts remain bullish on the stock’s prospects.
/Medtronic%20Plc%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Medtronic has outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.
/Insulet%20Corporation%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.
/Resmed%20Inc_%20HQ%20photo-by%20JHVEPhoto%20via%20iStock.jpg)
ResMed has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Stryker%20Corp_%20HQ%20sign%20-by%20Sundry%20Photography%20via%20Shutterstock.jpg)
Despite Stryker’s underperformance relative to the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
/Zimmer%20Biomet%20Holdings%20Inc%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Zimmer Biomet has significantly underperformed the broader market and other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.
/GE%20HealthCare%20Technologies%20Inc%20sign%20on%20building%20-by%20Poetra%20RH%20via%20Shutterstock.jpg)
Although GE HealthCare stock has lagged behind the broader market over the past year, analysts remain moderately bullish about its prospects.
/Steris%20Plc%20logo%20and%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
STERIS has outpaced its industry peers over the past year, and analysts are reasonably bullish on its future prospects.
/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Although Abbott Laboratories has underperformed its industry peers recently, analysts remain highly optimistic about the stock’s prospects.